Sold as Tace. Every FDA application for this active ingredient: 3 branded and 1 generic.
As of Nov 16, 2026, FDA lists 4 applications for Chlorotrianisene (sold as Tace), with 0 new uses approved and 0 published complete response letters.
| Transarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma (HCC) Prior to Liver TransplantationHCC - Hepatocellular Carcinoma · AIO-Studien-gGmbH | Not applicable | Recruiting | Nov 9, 2026 |
| Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver MetastasesNeuroendocrine Tumors · Chiyi Chen | — | Enrolling by invitation | Nov 3, 2026 |
| TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)Hepatocellular Carcinoma (HCC) · Zhongda Hospital | — | Not yet recruiting | Sep 23, 2026 |
| PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCCHepatocellular Carcinoma · Chang Gung Memorial Hospital | Phase 2 | Not yet recruiting | Sep 18, 2026 |
| Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular Carcinoma Undergoing TACETransarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization) · University Medical Center Ho Chi Minh City (UMC) | Not applicable | Active, not recruiting | Sep 17, 2026 |
| DNP-MRSI of HCC Metabolism to Predict Therapeutic ResponseBarcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC, Hepatocellular Carcinoma (HCC) · Abramson Cancer Center at Penn Medicine | — | Recruiting | Sep 8, 2026 |
| Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCCHepatocellular Carcinoma · Shanghai Zhongshan Hospital | — | Not yet recruiting | Aug 26, 2026 |
| SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaAdvanced Unresectable Hepatocellular Carcinoma · Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Aug 6, 2026 |
| — | ChlorotrianiseneANDA 84652 | Banner Pharmacaps | 0 | Discontinued |
| — | TaceNDA 8102 | Sanofi Aventis US | 0 | Discontinued |
| — | TaceNDA 11444 | Sanofi Aventis US | 0 | Discontinued |
| — | TaceNDA 16235 | Sanofi Aventis US | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA